Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Brain implant that learns: new hope for Parkinson's?

NCT ID NCT07216976

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 11, 2026 · Updated 2 times

Summary

This study tests an adaptive deep brain stimulation (aDBS) system that automatically adjusts stimulation based on real-time brain signals. It aims to improve symptom control for 62 people with Parkinson's disease in China who already have a compatible brain implant. The main goal is to see if aDBS can maintain or increase 'good on' time (symptom relief without troublesome movements) compared to standard continuous stimulation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Adaptive deep brain stimulation (aDBS) device
What this could lead to
If successful, this could offer a more personalized, responsive way to manage Parkinson's symptoms, potentially improving daily function without increasing side effects.
What could go wrong
This is a small, early-stage study (62 people) focused on feasibility and short-term outcomes. The adaptive algorithm may not work for everyone, and benefits over standard stimulation are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

61 people

The number who actually took part.

Started

Nov 2025

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subjects must meet all general inclusion/exclusion criteria (as assessed at the Enrollment Visit) 2. Subjects must meet the LFP screening inclusion criterion (as assessed at the LFP Screening Visit) General (Assessed at Enrollment Visit): 1. Subject has idiopathic Parkinson's disease 2. Subject is implanted (\>3 months prior to enrollment for new INS implants or \>1 month from INS replacement) with a Percept PC (Model B35200) or Percept RC (Model B35300) and Medtronic DBS leads (Model 3387, 3389, B33005 or B33015) and extensions (Model 37086 or B34000) bilaterally in the same target (physician confirmed), STN or GPi 3. In the opinion of the investigator, the subject responds to DBS Therapy. 4. Based on the opinion of the investigator, the subject's cDBS parameters and PD medications are stable (no changes within the last 4 weeks) and expected to remain stable from enrollment through the end of the aDBS Evaluation Phase 5. Subject is configured to monopolar or dual monopolar stimulation using contacts 1 and/or 2 (9 and/or 10) on at least one side 6. Subject is willing and able to attend all study-required visits and complete the study procedures (e.g. 1-month recall questionnaires, MDS-UPDRS III, Off stim/Off med visit) 7. Subject (or legally authorized representative) has the ability to understand and provide written informed consent for participation in the study prior to the study-related procedures being conducted 8. Subject is a male or non-pregnant female. If female of child-bearing potential, and if sexually active, must be using, or agree to use, a medically-acceptable method of birth control as confirmed by the investigator LFP Screening Inclusion Criteria (Conducted during LFP Screening Visit): 1\. Subject has Alpha - Beta band (8-30 Hz) amplitude ≥ 1.2 μVp detected on either left and/or right DBS leads on sensing channels 0-2, 0-3, 1-3, 8-10, 8-11, or 9-11. Exclusion Criteria: General (Assessed at the Enrollment Visit): 1. Subject and/or caregiver is unable to utilize the patient programmer 2. Subject has more than one lead in each hemisphere of the brain 3. Subject has cortical leads or additional unapproved hardware implanted in the brain 4. Subject has more than one INS 5. At enrollment, the subject's INS has a predicted battery life of \<1 year 6. Subject has Beck Depression Inventory II (BDI-II)\>25 7. Subject requires diathermy, transcranial magnetic stimulation (TMS), or electroconvulsive therapy (ECT) 8. Subject has a metallic implant in the head, (e.g., aneurysm clip, cochlear implant) 9. Subject has, or plans to obtain, an implanted electrical stimulation medical device anywhere in the body (e.g., cardiac pacemaker, defibrillator, spinal cord stimulator) 10. Subject has, or plans to obtain, an implanted medication pump for the treatment of Parkinson's disease (e.g., DUOPATM infusion pump) and/or portable infusion pump 11. Based on the opinion of the investigator, the subject has an abnormal neurological examination that would preclude them from study participation 12. Subject is breast feeding 13. Subject is under the age of 18 years 14. Subject is currently enrolled in or plans to enroll in any concurrent drug and/or device study that may confound the results of this study as determined by the Medtronic study team 15. Subjects with signal artifact on all 6 aDBS sense pathways (3 each on both DBS leads) which preclude the clinician from setting thresholds

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson's disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Huashan Hospital

    Shanghai, Shanghai Municipality, China

  • Ruijin Hospital

    Shanghai, Shanghai Municipality, China

  • Sun Yat-sen Hospital

    Guangzhou, Guangdong, China

  • West China Hospital

    Chengdu, Sichuan, China

  • Xuanwu Hospital

    Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.